Biotech Values

[DewDiligence]

XNPT -26% on AEs—mainly diarrhea—in phase-2 trial of XP23829 in psoriasis:

http://finance.yahoo.com/news/xenoport-announces-positive-phase-2-103000372.html

Diarrhea adverse event rates were consistent with other drugs in the fumaric acid ester class ranging from 22% to 40% in the XP23829 treatment groups compared with 15% for placebo. Other treatment emergent adverse events occurring at an incident rate of greater than or equal to 10% were nausea, abdominal pain, vomiting and headache.

I haven’t yet listened to the CC that was held this morning; the CC slide set is at: http://investor.xenoport.com/common/download/download.cfm?companyid=XNPT&fileid=850435&filekey=14A28021-A43C-4352-A7EE-F07A58551314&filename=XP23829_Phase_2_Preliminary_Topline_Presentation.pdf .